Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier
M
M
Division of Hypertension and Clinical Pharmacology, CHUV, Lausanne, Switzerland.
Buclin
T
T
Biollaz
J
J
Nussberger
J
J
Waeber
B
B
Brunner
H R
HR
D000804:Angiotensin II / Q000378:metabolism*; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D001562:Benzimidazoles / Q000493:pharmacokinetics / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics / Q000494:pharmacology; D000077405:Irbesartan; D019808:Losartan; D011355:Prodrugs / Q000493:pharmacokinetics / Q000494:pharmacology; D012016:Reference Values; D013777:Tetrazoles / Q000493:pharmacokinetics / Q000494:pharmacology
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007093:Imidazoles; D011355:Prodrugs; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan; D019808:Losartan; C077793:candesartan cilexetil